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1. Purpose of these guidelines
The European Society for Vascular Surgery appoints
Guidelines Committees to write clinical practice guidelines
for vascular surgery. Guidelines for the care of patients
with critical limb ischaemia accompany this commentary.
Guideline development was recommended in 1990 by
the Institute of Medicine, to improve decision-making
for speciﬁc patient circumstances, and to decrease the
variability between healthcare providers.1,2 Appropriate
decision-making is critical to achieving excellent outcomes.
Guidelines have become more popular in surgery and
medicine. This probably results from increased attention to
evidence-based medicine, the desire for reproducibility in
the choice of treatment for a speciﬁc patient, increasing
government legislation, the need to satisfy insurance
regulations, and legal pressures.
Critical limb ischaemia (CLI) is a complex condition and
there is signiﬁcant variability in clinical practice, although a
valid evidence base is available to guide recommendations.
The signiﬁcant increase in the volume of scientiﬁc literature
concerning critical limb ischaemia published in recent
years along with the number of technical and medical
advances supports guideline recommendations with more
certainty than before. Potential increases in healthcare
costs and risks due to industry and the public-driven use of
novel treatments, makes the current guidelines increasingly
important.3––6
Many clinical situations of patients with critical limb
ischaemia have not been the subject of randomised clinical
trials. Patient care, however, needs to be delivered and
decisions have to be made in these situations. Therefore,
this document should also provide guidance for decisions
where extensive Level 1 evidence is not available, and
recommendations are determined on the basis of the
currently available best evidence.
By providing information about the relevance and quality
of evidence, this document will enable the reader to
locate the most important and evidence-based information
relevant to the individual patient.7
To optimise the implementation of the current guideline
document, its length has been kept as short as possible
to enable easy access to its information. This document
is supposed to be a guide, not a set of rules, and allows
ﬂexibility for speciﬁc patient circumstances.
2. Methodology
The Critical Limb Ischaemia Guidelines Committee per-
formed a systematic literature search in the MEDLINE,
EMBASE and COCHRANE Library databases for each of
the different topics that are discussed in this guidelines
document. The Guidelines Committee used a grading system
based on levels of evidence and grades of recommendation
from the Oxford Centre for Evidence-Based Medicine.8 The
level of evidence classiﬁcation provides information about
the study characteristics supporting the recommendation,
according to the categories detailed in Table 1.
The recommendation grade indicates the strength of a rec-
ommendation. Deﬁnitions of the grades of recommendation
are given in Table 2.
The Critical Limb Ischaemia Guidelines Committee aims
to report the calculated estimates of effects, with their
95% conﬁdence intervals. Every part of the document has
been prepared by at least two members of the Committee
and has been reviewed by the entire Committee. The
initial document has been subsequently reviewed by the
CLI Guidelines Review Committee. After incorporation of
all comments and recommendations, these guidelines have
been submitted to the European Journal of Vascular &
Endovascular Surgery and peer reviewed.
3. Limitations
The guidelines should not be regarded as the only path to
follow, since every individual patient’s disease is unique.
This is particularly true in case of CLI, bearing in mind
that speciﬁc evidence for this selected population is still
limited, and patient characteristics, including geographic
location, can inﬂuence the suitability of a certain treatment
for a certain patient, and can limit the value of a single
recommendation.
1078-5884/$36 © 2011 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
S2 C. Setacci, J.-B. Ricco
Table 1 Levels of evidence
Level Therapy/Prevention, Aetiology/Harm Prognosis Diagnosis
1a SR (with homogeneity) of RCTs SR (with homogeneity) of inception
cohort studies; CDR validated in
different populations
SR (with homogeneity) of Level 1
diagnostic studies; CDR with 1b studies
from different clinical centres
1b Individual RCT (with narrow Conﬁdence
Interval)
Individual inception cohort study with
>80% follow-up; CDR validated in a
single population
Validating cohort study with good
reference standards; or CDR tested
within one clinical centre
1c All or none All or none case-series Absolute SpPins and SnNouts
2a SR (with homogeneity) of cohort studies SR (with homogeneity) of either
retrospective cohort studies or
untreated control groups in RCTs
SR (with homogeneity) of Level >2
diagnostic studies
2b Individual cohort study (including low
quality RCT; e.g., <80% follow-up)
Retrospective cohort study or follow-up
of untreated control patients in an
RCT; derivation of CDR or validated on
split-sample only
Exploratory cohort study with good
reference standards; CDR after
derivation, or validated only on
split-sample or databases
2c “Outcomes” research; ecological studies “Outcomes” research
3a SR (with homogeneity) of case––control
studies
SR (with homogeneity) of 3b and better
studies
3b Individual case-control study Non-consecutive study; or without
consistently applied reference standards
4 Case-series (and poor quality cohort and
case––control studies)
Case-series (and poor quality prognostic
cohort studies)
Case––control study, poor or
non-independent reference standard
5 Expert opinion without explicit critical
appraisal, or based on physiology, bench
research or “ﬁrst principles”
Expert opinion without explicit critical
appraisal, or based on physiology, bench
research or “ﬁrst principles”
Expert opinion without explicit critical
appraisal, or based on physiology, bench
research or “ﬁrst principles”
SR, systematic review; RCT, randomised controlled trial; CDR, clinical decision rule; SpPin, Speciﬁcity is so high that a positive result
rules-in the diagnosis; SnNout, Sensitivity is so high that a negative result rules-out the diagnosis.
Table 2 Grades of recommendation
Grade Strength
A Consistent Level 1 studies
B Consistent Level 2 or 3 studies or extrapolations from Level 1 studies
C Level 4 studies or extrapolations from Level 2 or 3 studies
D Level 5 evidence or troublingly inconsistent or inconclusive studies of any level
3.1. Appraisal of the level of evidence for critical limb
ischaemia
Since there are almost no RCTs dealing exclusively with CLI
patients, most of the lesser recommendations are based
on prospective evidence from subgroup analysis of “PAOD”
trials, or from prospective cohorts.
Where data originate from a RCT, the level of evidence
is given by that study design. Where results of subgroup
analysis are applied to a particular recommendation, it has
been downgraded according to the deﬁnitions above.
The concept of downgrading recommendations based on
extrapolation from higher-level studies may be considered a
limitation of these guidelines. In addition, in the absence of
the original data, downgrading published evidence carries
a risk of individual and arbitrary judgements unlikely to
be standardised and or standardisable. However, we accept
that there is an obvious risk of artiﬁcially inﬂating the
available evidence, which could lead to a false impression
of certainty, since evidence for the subset of CLI tends to be
extremely poor.
For example, since there are few RCTs directly comparing
surgical vs. endovascular treatment of CLI patients, there is
still a lack of objective grounds on which the choice between
the two approaches can be made.
In such cases the validation of a new technique (such
as an endovascular approach) does not depend only on a
comparison with the traditional technique (open surgery) but
also on the results that can be obtained by this treatment
with regard to the objectives for the treatment of CLI.
These objectives (limb salvage etc.) can clearly be reached
with the new technique and therefore there is evidence
for its use, but with a downgraded recommendation. To
require that the evidence depend on the presence of direct
comparisons with the traditional technique could also be
reversed: there is no absolute evidence for the traditional
technique as there are no RCTs comparing this to the new
technique.
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3.2. Geography-related factors
The importance of geographic factors in the choice of
treatment and eventual prognosis in vascular disease
has been addressed only infrequently. However, these
differences can be partly responsible for the contradictory
results of different studies, with an apparently similar
design.
Previous studies have reported on the importance of
geographic inﬂuences on the outcome of treatment of
vascular disease. Singh et al. reported that the incidence
of angiographic restenosis and ischaemia-driven revascular-
isations after percutaneous coronary interventions differed
substantially between patients treated in the USA compared
with other countries mainly located in Western Europe.9
Moreover, large differences in amputation rates due to
gangrene in patients with diabetes originating from different
geographic regions, were reported by Chaturvedi and co-
workers.10 Differences in mortality due to cardiovascular
disease and cerebrovascular disease are also striking even
within the same continent as has been reported by Levi
et al.11 Similar differences in the incidence of cardiovascular
disease within quite closely related geographic areas have
been reported by others, for example between Northern
and Southern European countries.12,13 The differences in
clinical outcomes are also reﬂected in the composition
of atherosclerotic plaques reported by Tanganelli et al.14
Literature addressing the mechanical underpinnings of these
geographic variances in cardiovascular disease incidence and
outcome is scarce, but genetics, dietary factors and other
environmental and life style-related factors are likely to play
a role.
It is likely that the geographic inﬂuence on cardiovascular
disease incidence and outcome is reﬂected by plaque com-
position, and has at least some inﬂuence on the durability
and efﬁcacy of vascular reconstructions. Therefore, the
results of studies originating from countries different from
where the vascular surgeon works should be interpreted
cautiously.
Since we aim for an European Society for Vascular Surgery-
wide distribution of this guideline we did not speciﬁcally
address the geographic origin of the studies, but it should
be stressed that these factors should be borne in mind when
reading it. Moreover, the ethnic and geographic mechanisms
underlying the observed differences should receive more
attention in future studies.
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